Lyell Immunopharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
201 Haskins Way South, South San Francis...Phone Number
(650) 695-0677Website
www.lyell.comRevenue
<$5 MillionStock Symbol
LYELIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Lyell Immunopharma
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. We are pioneering novel T-cell reprogramming technologies designed to address major barriers to effective cell therapy for solid tumors.Explore more
Lyell Immunopharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lyell Immunopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Lyell Immunopharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Lyell Immunopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Lyell Immunopharma has new funding data
Check out if Lyell Immunopharma is spiking on competitors!
Click to see if Lyell Immunopharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Lyell Immunopharma
Product Launch: Get notified when Lyell Immunopharma launches new products
Check if Lyell Immunopharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Lyell Immunopharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to Lyell Immunopharma
Compare insights from companies similar to Lyell Immunopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lyell Immunopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lyell Immunopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lyell Immunopharma.
Lyell Immunopharma financials insights
Gather financial insights about Lyell Immunopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$100M
Lyell Immunopharma Tech Stack
A closer look at the technologies used by Lyell Immunopharma
See more technologies
Most Recent Scoops
Hiring Plans
Lyell Immunopharma has more open roles in Operations than it has had at any time in the past 12 months. Areas of expertise include: Functional Excellence.
Hiring Plans
Open Position
Open Position
Project
Lyell Immunopharma is developing LYL273, a novel CAR for patients with metastatic colorectal cancer, currently in a trial for patients in the third or later line.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Clinical Operations
Lyell Immunopharma News & Media
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today provided an update on the safety profile of LYL273 in its ongoing U.S. Phase 1 clinical trial in patients with relapsed or refractory metastatic colorectal cancer (mCRC), and announced the Phase 1 trial has been amended to enable seamless expansLyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that the Company will present data from its ongoing Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) at the European Hematology Association (EHLyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8, 2026, in Miami, Florida, with a fireside chat scheduled for 11:20 am Eastern Time.Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances
Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel. Seely described Lyell as a cell therapy c
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lyell Immunopharma
Sign Up For FreeTo access detailed company insights
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. We are pioneering novel T-cell reprogramming technologies designed to address major barriers to effective cell therapy for solid tumors.... Read More
